{"filing":{"accession_number":"0001213900-26-067083","cik":"0001713863","ticker":"RFL","company_name":"Rafael Holdings, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"ea0294151-8k_rafael.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1713863/000121390026067083/ea0294151-8k_rafael.htm"},"events":[{"id":5690,"run_id":4983,"accession_number":"0001213900-26-067083","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Rafael Holdings announced completion of the final 96-week study visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data expected in H2 2026. This represents a material clinical milestone for the company's lead therapeutic candidate.","company_name":"Rafael Holdings, Inc.","ticker":"RFL","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5723,"accession_number":"0001213900-26-067083","item_number":"7.01","item_title":"Regulation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Rafael Holdings announced completion of the final 96-week study visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data expected in H2 2026. This is a material clinical milestone for a biotech company with a lead therapeutic candidate, affecting investor assessment of pipeline progress and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or executive change), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:50:08.116738+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5724,"accession_number":"0001213900-26-067083","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.35,"reasoning":"Item 8.01 incorporates Item 7.01 by reference but provides no substantive disclosure in this section. Without access to Item 7.01's content, the materiality and specific event type cannot be determined. This appears to be a cross-reference placeholder rather than a standalone disclosure, making classification highly uncertain.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:50:08.116738+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5723,"accession_number":"0001213900-26-067083","item_number":"7.01","item_title":"Regulation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Rafael Holdings announced completion of the final 96-week study visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data expected in H2 2026. This is a material clinical milestone for a biotech company with a lead therapeutic candidate, affecting investor assessment of pipeline progress and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or executive change), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:50:08.116738+00:00","company_name":"Rafael Holdings, Inc.","ticker":"RFL","filing_date":"2026-06-10"},{"id":5724,"accession_number":"0001213900-26-067083","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.35,"reasoning":"Item 8.01 incorporates Item 7.01 by reference but provides no substantive disclosure in this section. Without access to Item 7.01's content, the materiality and specific event type cannot be determined. This appears to be a cross-reference placeholder rather than a standalone disclosure, making classification highly uncertain.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:50:08.116738+00:00","company_name":"Rafael Holdings, Inc.","ticker":"RFL","filing_date":"2026-06-10"}]}